135 related articles for article (PubMed ID: 35448195)
1. Prognostic Relevance of Weight and Weight Loss during Multimodal Therapy for Oesophagogastric Tumours.
Lorusso A; Bichev D; Högner A; Bartels P; Ballhausen A; Treese C; Biebl M; Thuss-Patience P
Curr Oncol; 2022 Apr; 29(4):2706-2719. PubMed ID: 35448195
[TBL] [Abstract][Full Text] [Related]
2. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
[TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
4. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
5. A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer.
Anderson E; LeVee A; Kim S; Atkins K; Guan M; Placencio-Hickok V; Moshayedi N; Hendifar A; Osipov A; Gangi A; Burch M; Waters K; Cho M; Klempner S; Chao J; Kamrava M; Gong J
JAMA Netw Open; 2021 Dec; 4(12):e2138432. PubMed ID: 34889947
[TBL] [Abstract][Full Text] [Related]
6. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
7. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
[TBL] [Abstract][Full Text] [Related]
8. Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection?
Rosumeck N; Timmermann L; Klein F; Bahra M; Stintzig S; Malinka T; Pelzer U
Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33477505
[No Abstract] [Full Text] [Related]
9. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy.
Powell AGMT; Karran A; Blake P; Christian A; Roberts SA; Lewis WG
BJS Open; 2020 Aug; 4(4):593-600. PubMed ID: 32374504
[TBL] [Abstract][Full Text] [Related]
10. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
[TBL] [Abstract][Full Text] [Related]
11. Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy.
Ballhausen A; Bartels P; Iacovella I; Hoegner A; Lorusso A; Bichev D; Daum S; Thuss-Patience P
Curr Oncol; 2022 Mar; 29(3):1983-1996. PubMed ID: 35323361
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
14. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
[TBL] [Abstract][Full Text] [Related]
15. Association of Weight Change, Inflammation Markers and Disease Staging with Survival of Patients Undergoing Chemotherapy for Pancreatic Adenocarcinoma.
Vasconcelos de Matos L; Coelho A; Cunha R; Fernandes L; Fontes E Sousa M; Neves MT; Cardoso D; Malheiro M; Graça J; Santos Silva E; Plácido A; Martins A
Nutr Cancer; 2022; 74(2):546-554. PubMed ID: 33749421
[TBL] [Abstract][Full Text] [Related]
16. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M
Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585
[TBL] [Abstract][Full Text] [Related]
17. Baseline neutrophil-lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy.
van Hootegem SJM; Smithers BM; Gotley DC; Brosda S; Thomson IG; Thomas JM; Gartside M; Barbour AP
Dis Esophagus; 2020 Jun; 33(6):. PubMed ID: 31676907
[TBL] [Abstract][Full Text] [Related]
18. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
19. Marked loss of adipose tissue during neoadjuvant therapy as a predictor for poor prognosis in patients with gastric cancer: A retrospective cohort study.
Zhang Y; Li Z; Jiang L; Xue Z; Ma Z; Kang W; Ye X; Liu Y; Jin Z; Yu J
J Hum Nutr Diet; 2021 Jun; 34(3):585-594. PubMed ID: 33491826
[TBL] [Abstract][Full Text] [Related]
20. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
